None
Quote | ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Last: | $18.49 |
---|---|
Change Percent: | 0.0% |
Open: | $18.2 |
Close: | $18.49 |
High: | $18.5 |
Low: | $18.05 |
Volume: | 1,481,490 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
2024-03-26 14:13:56 ET Summary Neurogene Inc., a clinical-stage company focused on genetic medicines for rare neurological diseases, has seen a significant increase in its share price since joining the Nasdaq in December 2023. The company is progressing two drug candidates, NGN-40...
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Pharmaceuticals Inc. ("Acadia " or "the Company") (NASDAQ:ACAD). Investors who purchased Acadia securities prior to September 9, 2019, and conti...
Message Board Posts | ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ACAD News Article - Acadia Pharmaceuticals Announces DAYBUE(TM) (trofinetide) is Now A | whytestocks | investorshangout | 04/17/2023 2:40:49 PM |
Is Martin Shkreli in charge of Acadia, or | Doktornolittle | investorshub | 04/09/2023 12:01:33 PM |
30s coming folks, patience | harry crumb | investorshub | 03/13/2023 10:57:16 PM |
$ACAD hopefully Opening will give a boost but | MiamiGent | investorshub | 03/13/2023 1:02:22 PM |
If the price is right, yes | harry crumb | investorshub | 03/13/2023 11:34:59 AM |
News, Short Squeeze, Breakout and More Instantly...
ACADIA Pharmaceuticals Inc. Company Name:
ACAD Stock Symbol:
NASDAQ Market:
ACADIA Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Pharmaceuticals Inc. ("Acadia " or "the Company") (NASDAQ:ACAD). Investors who purchased Acadia securities prior to September 9, 2019, and conti...
2024-03-25 11:30:02 ET RBC Capital analyst issues BUY recommendation for ACAD on March 25, 2024 10:00AM ET. The previous analyst recommendation was Buy. ACAD was trading at $17.85 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s ...